History

OPTITHERA is a Precision Medicine company focusing on the discovery and clinical application of genomic signatures predictive of susceptibility to type 2 diabetes (T2D) complications.

OPTITHERA Inc. was founded in 2014 by two Professors of the Université de Montréal, Johanne Tremblay and Pavel Hamet (Canada Research Chair in Predictive Genomics). The company aims at becoming an important hub in the Precision Medicine market of diabetes and its complications.

 

Corporate Objectives:

• To commercialize its direct-to-consumer (DTC) genetic health risk tests for patients diagnosed with T2D. 

• To develop strategic partnerships with North American distributors (Quebec, Canada & USA)

• To develop strategic partnerships with Pharmaceutical companies to assist them with recruitment of subjects in their clinical trials on diabetes.

• To commercialize genetic health risk tests for T2D patients of various ethnic groups.

 

 

MANAGEMENT & TEAM

Pavel Hamet
CM, OQ, MD, PhD, FRCPC, FAHA, FRSM, FCAHS

Founding President of OPTITHERA & Chief Medical Officer

 

Dr. Hamet holds a Canada Research Chair in Predictive Genomics. He is Professor of Medicine at the Université de Montréal, Adjunct Professor of Experimental Medicine at McGill University, and Visiting Professor at the First Faculty of Medicine at Charles University, Prague, Czech Republic.

 

He founded and directed the Centre Hospitalier de l’Université de Montréal (CHUM) Research Centre (CRCHUM) from 1996 to 2006. He is currently Chief of Gene Medicine at CHUM. He is the author of more than 600 scientific publications in diabetes and hypertension and is recognized as an international leader in personalized medicine of cardiometabolic diseases.

Johanne Tremblay, PhD, FAHA, FCAHS
Co-founder, Vice-President and Chief Scientific Officer

 

Professor of Medicine at the Université de Montréal & Fellow of the Canadian Academy of Health Sciences and of the American Heart Association, she has authored more than 300 scientific publications and holds several patents in the area of diabetes, cardiovascular diseases and personalized medicine. She chaired the programme committees of First and Second Congresses of Personalized healthcare in Montreal with participation of scientists from over 25 countries.

Martin Godbout, OC, PhD
Chief Executive Officer of OPTITHERA

 

Following a Ph.D. in Molecular Endocrinology from Laval University in the early 90’s, Martin Godbout was named President and general manager of Société Innovatech Québec, a technology venture capital fund (60 M$). In 1997, he became the executive VP of BioCapital II, a biopharmaceutical venture fund (60M$). In May 2000, he became the President and CEO of Genome Canada, for the next 10 years (1.4 B$). In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of ten nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world”.

Pierre Dumas, PhD
Administrative Director

 

With more than 18 years of experience in clinical and basic research, Pierre Dumas has worked on large scale projects in the United States (NHLBI SCOR and PGA programs) and Canada (CFI, Genome Quebec and CART@GENE). He has long-standing experience in management of high throughput facilities with experience ranging from budgets, contracts and RS&DE tax credits to ethics board applications. He is experienced in all phases of clinical research. Pierre holds a Ph.D. (biomedical sciences) from the University de Montréal and completed four years of post-doctoral training in cardiovascular genetics at the Medical College of Wisconsin and at McGill University.

Candan Hizel Perry, PhD
Pharmacogenetics Director

 

Dr. Hizel has more than 17 years of experience in personalized medicine, including pharmacogenomics (PGx) association studies, biomarker research, clinical diagnostics, health communications, health information technology, health behaviour changes and health systems improvement in both high-income country (HIC) and in low-and middle-income country (LMIC) settings. Between 1999 and 2005, he was research director and vice-president within the R&D department of a genomics/PGx bioinformatics consulting company in Clermont-Fd/France and in Montreal/Canada, respectively. 

IN THE NEWS

December 12 2019
Congrès InnovAction au @CHUM
Conférence sur la médecine personnalisé...
November 21 2019
Polygenic risk: What’s the score?
Researchers are improving risk prediction [NATURE]...
November 1 2019
Polygenic risk scores predict diabetic complications and their response to therapy
Type 2 diabetes increases the risk of cardiovascular and renal complications, but early risk prediction can lead to timely intervention and better...
English English French French